Pharma-grade expansion SOLVD Health has secured FDA approval for its AvertD pharmacogenomic test for opioid use disorder, signaling a trajectory into regulated clinical diagnostics and potential partnerships with payors, labs, and treatment centers seeking pharmacogenomic solutions.

Board-level momentum Recent additions to the Board of Directors, including diagnostics pioneers, indicate a strategic push toward scale, governance strength, and partnerships with biotech investors and healthcare incumbents that can open doors for collaboration and co-development opportunities.

Clinical leadership New senior leadership in clinical operations and financial oversight suggests solid execution capabilities for clinical programs and scalable operations, making SOLVD Health a candidate for managed services, data integrations, and outsourced validation partnerships.

Patient Intelligence The company’s core mission around actionable patient health insights positions it for collaboration with health systems, PBMs, and digital health platforms seeking integration of predictive signals, risk stratification, and personalized prevention programs.

Growth signals With 10–25 million in revenue and a growing tech stack usage (CRM, analytics, cloud, and e-commerce tools), SOLVD Health appears poised for channel partnerships, co-marketing with CROs/diagnostics firms, and strategic alliances to scale go-to-market and data capabilities.